The week's View summarizes the 10-year follow-up of the SYNTAX trial (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) and offers key points to remember from an article about lipid management for the prevention of atherosclerotic cardiovascular disease and a state-of-the-art review on the clinical and prognostic significance of soluble suppression of tumorigenesis-2 in heart failure.
↧